In an ongoing phase I/II trial, WU-NK-101, the company's lead product, demonstrated an impressive complete response rate in relapsed/refractory AML, Wugen said. The company will also apply proceeds to advance its broader pipeline of next-generation products, including an allogeneic CD7-targeted CAR T cell therapy to treat T-cell leukemia and lymphoma.

The round of series B funding was co-led by Abingworth and Tybourne Capital Management.

Inceptor Bio launches FastBack Bio
Inceptor Bio has launched its first portfolio company, Fastback Bio, to accelerate the development of T cell-based therapies targeting difficult to treat...

CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...

Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration
Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing...

Kytopen granted SBIR for nonviral NK cell gene editing platform
Kytopen has been awarded a Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases to demonstrate...

ONK obtains license for NK cells for cancer treatment
ONK Therapeutics announced it inked a patent license deal with Australia's Walter and Eliza Hall Institute of Medical Research for rights to CISH knockout...